EDX Medical Group PLC Strategic investment from Boru Ltd (4492E)
30 Junho 2023 - 3:00AM
UK Regulatory
TIDMEDX
RNS Number : 4492E
EDX Medical Group PLC
30 June 2023
This announcement contains inside information as stipulated
under the UK version of the Market Abuse Regulation No 596/2014
which is part of English law by virtue of the European (Withdrawal)
Act 2018, as amended. On publication of this announcement via a
regulatory information service, this information is considered to
be in the public domain.
Strategic investment from Boru Ltd
EDX Medical Group Plc -- EDX
30 June 2023
EDX Medical Group PLC ("EDX Medical" or the "Company"), which
develops innovative digital diagnostic products and services
supporting personalised treatment solutions for cancer, heart
disease, neurology and infectious diseases, announces that the
Company has received a strategic investment of GBP500,000 from Boru
Ltd ("Boru") via a subscription of 6,250,000 new ordinary shares of
1p each in the Company ("Ordinary Shares") at a price of 8p per
share (the "Subscription", "Subscription Shares").
Boru is a private investment company which invests in growth
companies on a global basis in order to achieve its financial
goals.
The investment in the Company by Boru will be used to support
the expansion of EDX Medical's capabilities and support clients
providing personalised care for cancer patients in the UK and
Europe.
An application has been made for the Subscription Shares to be
admitted to trading on the AQSE Growth Market and admission is
expected to become effective on, July 5, 2023.
Professor Sir Chris Evans, OBE, founder of EDX Medical,
commented:
"We are delighted Boru has made an investment in EDX Medical as
they are well-known investors in growth companies they believe are
capable of delivering innovative and impactful new products and
services. We appreciate their confidence in backing our digital
diagnostics strategy."
Dr Mike Hudson, Chief Executive Officer of EDX Medical,
commented:
"This investment will help us to accelerate our programme to
develop and acquire the key products and technologies required to
deliver the benefits of personalised medicine for patients in the
UK & Europe."
Total Voting Rights
In accordance with the Financial Conduct Authority's Disclosure
and Transparency Rules, the Company hereby announces that following
the Subscription, it has 291,875,000 Ordinary Shares in issue, each
share carrying the right to one vote.
The above figure of 291,875,000 Ordinary Shares may be used by
shareholders in the Company as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of
the Company under the Financial Conduct Authority's Disclosure and
Transparency Rules.
The directors of EDX Medical accept responsibility for the
contents of this announcement.
Contacts:
EDX Medical PLC
Dr Mike Hudson (Chief Executive Officer) +44 (0)7812 345 301
mike@edxmedical.co.uk
Oberon Capital
Nick Lovering (Corporate Adviser)
Adam Pollock (Corporate Broking)
Mike Seabrook (Corporate Broking) +44 (0)20 3179 5300
Media House International
Ramsay Smith (Executive Director) +44 (0)7788 414856
ramsay@mediahouse.co.uk
Gary McQueen (Associate Director) + 44 (0)7834 694609
gary@mediahouse.co.uk
Notes for Editors:
About EDX Medical Group
www.edxmedical.co.uk
EDX Medical Group PLC develops innovative digital diagnostic
products and services, enabling cost effective and timely delivery
of personalised treatment for cancer, heart disease, neurology and
infectious diseases. The company is listed on the Access Segment of
the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE,
a medical and life sciences entrepreneur with more than 30 years of
experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions
combining advanced biological and digital technologies, EDX Medical
seeks to cost-effectively improve the detection and
characterisation of disease in order to personalise treatment in a
timely fashion. Early disease detection and biologically-based
personal treatment optimisation is considered to be the most
impactful way of reducing deaths and lowering the cost of
healthcare globally.
EDX Medical operates a molecular biology and diagnostics
laboratory in Cambridge, UK, and the 100%-owned subsidiary "Torax
Biosciences Ltd" ( www.toraxbiosciences.co.uk ) with a satellite
operation in Ireland. EDX Medical provides testing and genomic
sequencing services, undertakes quality assurance, conducts
research & development (R&D) and has established expertise
in the design, development, validation and sourcing of diagnostic
testing solutions to ISO 13485. Key laboratory tests performed by
the Company have been accredited to ISO 15189 by the United Kingdom
Accreditation Service (UKAS).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXUKANRONUNUAR
(END) Dow Jones Newswires
June 30, 2023 02:00 ET (06:00 GMT)
EDX Medical (AQSE:EDX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
EDX Medical (AQSE:EDX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
